Model-informed COVID-19 vaccine prioritization strategies by age and serostatus.
Science
; 371(6532): 916-921, 2021 02 26.
Article
in English
| MEDLINE | ID: covidwho-1532943
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mass Vaccination
/
COVID-19 Vaccines
/
COVID-19
/
Health Priorities
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Humans
/
Middle aged
/
Young adult
Language:
English
Journal:
Science
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS